Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- MRNS
- Price
- 0.55
- Stock movement up
- +- (%)
- Company name
- Marinus Pharmaceuticals Inc
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 30.35M
- Ent value
- 118.53M
- Price/Sales
- 0.96
- Price/Book
- -
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- -6.04%
- 1 year return
- -94.49%
- 3 year return
- -62.46%
- 5 year return
- -42.25%
- 10 year return
- -35.47%
Last updated: 2025-04-12
DIVIDENDS
MRNS does not pay dividends or no data was received
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 0.96 |
| Price to Book | - |
| EV to Sales | 3.77 |
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 55.19M |
| EPS (TTM) | -2.45 |
| FCF per share (TTM) | -2.03 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 31.47M |
| Gross profit (TTM) | 27.98M |
| Operating income (TTM) | -124.57M |
| Net income (TTM) | -140.49M |
| EPS (TTM) | -2.45 |
| EPS (1y forward) | -0.72 |
Margins
Loading...
Margins data
| Gross margin (TTM) | 88.92% |
| Operating margin (TTM) | -395.90% |
| Profit margin (TTM) | -446.49% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 42.18M |
| Net receivables | 3.84M |
| Total current assets | 57.40M |
| Goodwill | 0.00 |
| Intangible assets | 0.00 |
| Property, plant and equipment | 0.00 |
| Total assets | 63.62M |
| Accounts payable | 3.71M |
| Short/Current long term debt | 55.99M |
| Total current liabilities | 34.50M |
| Total liabilities | 130.36M |
| Shareholder's equity | -66.74M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -114.75M |
| Capital expenditures (TTM) | 1.19M |
| Free cash flow (TTM) | -115.93M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | - |
| Return on Assets | -220.81% |
| Return on Invested Capital | 267.80% |
| Cash Return on Invested Capital | 220.99% |
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 0.55 |
| Daily high | 0.55 |
| Daily low | 0.55 |
| Daily Volume | 0K |
| All-time high | 77.52 |
| 1y analyst estimate | 1.47 |
| Beta | 1.26 |
| EPS (TTM) | -2.45 |
| Dividend per share | - |
| Ex-div date | - |
| Next earnings date | 6 May 2025 |
Downside potential
Loading...
Downside potential data
| MRNS | S&P500 | |
| Current price drop from All-time high | -99.29% | -0.73% |
| Highest price drop | -99.70% | -56.47% |
| Date of highest drop | 23 Dec 2024 | 9 Mar 2009 |
| Avg drop from high | -77.99% | -11.07% |
| Avg time to new high | 147 days | 12 days |
| Max time to new high | 2396 days | 1805 days |
COMPANY DETAILS
Marketcap
30.35M
Marketcap category
Small-cap
Description
Marinus Pharmaceuticals, Inc., a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings. The company's ZTALMY product candidate acts at synaptic and extrasynaptic GABAA receptors, a target for its anti-seizure, antidepressant, and anxiolytic potential. It is developing ganaxolone for treating genetic epilepsy disorders, such as PCDH19-related epilepsy, and tuberous sclerosis complex. Marinus Pharmaceuticals, Inc. has license agreement with Purdue Neuroscience Company and CyDex Pharmaceuticals, Inc.; and collaboration agreement with Orion Corporation and Tenacia Biotechnology (Shanghai) Co., Ltd. Marinus Pharmaceuticals, Inc. was incorporated in 2003 and is headquartered in Radnor, Pennsylvania.
Employees
165
Website
Investor relations
-
SEC filings
CEO
Scott N. Braunstein
Country
USA
City
Radnor
Stock type
Common stock
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
No items found
iO Charts is a Seeking Alpha partner